Powered by
-Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(4)

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted six newly-hired employees options to purchase an aggregate of 30,500 shares of Akebia's common stock with a per share exercise price of $ 14.87, the closing price on the grant date.

These options will vest as to 25% of the total numbe

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox